Cortexin, 5mg , 10 pcs. (for children)

1 bottle with lyophilisate contains:

active substance:

cortexin (complex of water-soluble polypeptide fractions) 5 mg,

excipient:

vglycine (stabilizer) 12 mg

CORTEXIN contains a complex of low molecular weight water-soluble polypeptide fractions that cross the blood-brain barrier directly to nerve cells. The drug has a nootropic, neuroprotective, antioxidant and tissue-specific effect. Nootropic - improves higher brain functions, learning and memory processes, concentration of attention, resistance to various stressful effects.

Neuroprotective - protects neurons from damage by various endogenous neurotoxic factors (glutamate, calcium ions, free radicals), reduces the toxic effects of psychotropic substances.

Antioxidant - inhibits lipid peroxidation in neurons, increases the survival of neurons under conditions of oxidative stress and hypoxia. Tissue-specific - activates the metabolism of neurons of the central and peripheral nervous system, reparative processes, improves the functions of the cerebral cortex and the general tone of the nervous system.

Mechanism of action

CORTEXIN is caused by activation of peptides of neurons and brain neurotrophic factors; optimization of the balance of metabolism of excitatory and inhibitory amino acids, dopamine, serotonin; GABAergic effect; a decrease in the level of paroxysmal convulsive activity of the brain, the ability to improve its bioelectric activity; preventing the formation of free radicals (products of lipid peroxidation).

Pharmacokinetics

The composition of CORTEXIN, the active substance of which is a complex of polypeptide fractions, does not allow the usual pharmacokinetic analysis of individual components.

In complex therapy:

• cerebrovascular accident;
• TBI and its consequences;
• encephalopathies of various origins;
• cognitive impairment (memory and thinking disorders);
• acute and chronic encephalitis and encephalomyelitis;
• epilepsy;
• asthenic conditions (suprasegmental autonomic disorders);
• reduced learning ability;
• delayed psychomotor and speech development in children;
• various forms of cerebral palsy.

Individual intolerance to the drug.

The drug is contraindicated during pregnancy (due to lack of clinical trial data).

If it is necessary to prescribe the drug during lactation, breast-feeding should be stopped (due to lack of clinical trial data).

No side effects have been reported.

Individual hypersensitivity to the components of the drug is possible.

The drug is administered intramuscularly.

The contents of the vial before injection are dissolved in 1-2 ml of a 0.5% solution of procaine (novocaine), water for injection or 0.9% sodium chloride solution, directing the needle to the wall of the vial to avoid foaming, and administered once daily: for adults at a dose of 10 mg for 10 days; children with a body weight of up to 20 kg at a dose of 0.5 mg / kg, with a body weight of more than 20 kg - at a dose of 10 mg for 10 days.

If necessary, repeat the course after 3-6 months. For hemispheric ischemic stroke in the acute and early recovery periods, adults at a dose of 10 mg 2 times a day (morning and afternoon) for 10 days, with a second course after 10 days.

Lyophilisate for solution for intramuscular administration